• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

World J Hepatol . Transaminitis is an indicator of mortality in patients with COVID-19: A retrospective cohort study

tetano

Editor, Senior Moderator
World J Hepatol


. 2020 Sep 27;12(9):619-627.
doi: 10.4254/wjh.v12.i9.619.
Transaminitis is an indicator of mortality in patients with COVID-19: A retrospective cohort study


Vishnu Charan Suresh Kumar[SUP] 1 [/SUP], Prateek Suresh Harne[SUP] 2 [/SUP], Samiran Mukherjee[SUP] 2 [/SUP], Kashvi Gupta[SUP] 3 [/SUP], Umair Masood[SUP] 4 [/SUP], Anuj Vikrant Sharma[SUP] 4 [/SUP], Jivan Lamichhane[SUP] 2 [/SUP], Amit Singh Dhamoon[SUP] 2 [/SUP], Bishnu Sapkota[SUP] 4 [/SUP]



Affiliations

Abstract

Background: Since its discovery in Wuhan, China in December of 2019, the novel coronavirus has progressed to become one of the worst pandemics seen in the last 100 years. Recently, there has been an increased interest in the hepatic manifestations of coronavirus disease 19 (COVID-19).
Aim: To describe the demographic and clinical characteristics of COVID-19 positive patients and study the association between transaminitis and all-cause mortality.
Methods: This is a descriptive retrospective cohort study of 130 consecutive patients with a positive COVID PCR test admitted between March 16, 2020 to May 14, 2020 at a tertiary care University-based medical center. The Wilcoxon-rank sum test and paired t-test were used for comparing non-parametric and parametric continuous variables respectively and a multivariable logistic regression models to study the association between transaminitis and mortality using SAS version 9.4 (SAS Institute, Cary, NC, United States).
Results: Out of the 130 patients, 73 (56%) patients were found to have transaminitis and 57 (44%) did not. When compared to patients without transaminitis, the transaminitis group was found to have a higher median body mass index (30.2 kg/m[SUP]2[/SUP]vs 27.3 kg/m[SUP]2[/SUP], P = 0.04). In the multivariate analysis those with transaminitis were found to have 3.4 times higher odds of dying as compared to those without transaminitis adjusting for gender, the Age-adjusted Charlson Comorbidity Index and admission to the intensive care unit (P = 0.03).
Conclusion: Our study showed that transaminitis on admission was associated with severe clinical outcomes such as admission to the intensive care unit, need for mechanical ventilation, and mortality.

Keywords: Alanine aminotransferase; Aspartate aminotransferase; COVID-19; Liver; Liver enzymes; Mortality; Transaminitis.
 
Back
Top Bottom